摘要
目的研究吗替麦考酚酯在原发性肾病综合征患者中的群体药动学模型,为临床个体化用药提供参考。方法选取2011年1月-2014年2月期间我院收治的56例原发性肾病综合征患者作为本组研究的观察对象,所有患者在给予吗替麦考酚酯对症治疗后,采集其血液样本,通过非线性混合效应模型构建出麦考酚酯的群体药动学模型,从而探讨患者的年龄、性别、身高、体重、剂量、血清肌酐、治疗时间等对药动学参数的影响。结果药动学基本模型采用一级吸收和消除的二房室模型最为有效;患者体重与治疗时间是吗替麦考酚酯清除率的主要因素;最终群体药动学模型为：清除率=0.476×体重×（1-e^-1.17POD）。结论吗替麦考酚酯在原发性肾病综合征患者中的药动学模型具有明显的代表性,为个体化给药方案的确定提供依据。
Objective To study population pharmacokinetic model of mycophenolate mofetil （MMF） in primary nephrot- ic syndrome （PNS） in order to provide a reference for clinical personalized medication. Methods From January 2011 to February 2014,56 patients with PNS admitted into our hospital were selected as observation objects during the study. Symptomatic treatment of MMF was provided in all participants,and then blood samples were collected.Population pharmacokinetic model of MMF was constructed by nonlinear mixed effect model aiming at exploring the influences of patient＇s age,gender,height,weight,dosage,serum ereatinine,and treatment time on the pharmacokinetie parameters. Re- suits Two-compartment model of first-order absorption and elimination in pharmaeokinetie basic model were most effective.Weight and treatment time were principal factors in MMF clearance rate.The final population pharmaeokinetie model： clearance rate = 0.476xtotal body weightx（1-e^-1.17POD）, Conclusion MMF is representative in pharmacokinetic model in PNS and provides the basis for determining individualized dosage regimen.
出处
《中国当代医药》
2015年第21期4-6,共3页
China Modern Medicine
关键词
吗替麦考酚酯
群体药动学
非线性混合效应模型
Mycophenolate moftil
Population pharmacokinetics
Nonlinear mixed effect model
